According to Zacks Equity Research, it shouldn't be surprising that CDNS is a #2 stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Cadence Design Systems on your short list.
Preliminary studies on coronavirus vaccines have produced promising results. I'm still a believer in their technology. Check out my previous NVAX posts and/or the first one. They have a promising technology that could revolutionize the vaccine industry. We (humanity) are already very behind in how we produce vaccines AKA using chicken eggs. So Novavax will...
📈 NVAX LONG D1 🛒BUY above = 156 🎯Target1 = 172 🎯Target2 = 201 🛑Stop loss = 1126 🙈Risk = (1%-2%) #NVAX #NVAXLONG #BUYNVAX
Hello traders! Good news from Novavax! The chances of approval for flu vaccine candidate NanoFlu seems actually quite good! Moreover, if we look at the chart, we can see that the price is on a strong uptrend that doesn't seem to want to stop. The bullish momentum is still strong! Remember to put a stop loss in order to secure your capital! Not a financial...
Chalice Golde Mines Major Breakout of 10 year base. The bigger the base the higher in space. Three district scale exploration properties in the best and most prolific areas in Australia. Tier one assets. Exploring near some of the most profitable mines in the world including the Fosterville Gold Mine owned by Kirkland Lake Gold (NYSE / TSX: KL | ASX: KLA) and...
Earlier today, I put a target of at most $115 and later was convinced to do a sell off at $108. Many people thought this would go straight to $150+, but it looks like the positive wedge have peaked. Right now, I currently think the dip will likely be at the $90 price point, but an important factor to consider is closely monitoring movement at the $95 mark. The...
Hi Guys, changed up the strategy a little today and $BA was not easy to trade. Enjoy, Enda
I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my...
Link to Culper Research report that states they are shorting VBIV because the company is "worthless" img1.wsimg.com First, it's always important to consider ALL information. It's also important to be transparent about knowledge. If you are going to make any VBIV trades you really should read the entire report. 1) I think many of the points made in the Culper...
I've been following NVAX since price was at $12. Fundamentally they have one of the most promising COVID vaccines and their Nano Flu shot beat Sanify's flu shot, whos been a market majority holder in that aspect. Technically, we've tapped that $150+ zone 8 out of the last 9 fast rises over since the company IPO'd in 1996. Each of the rises have been driven by...
Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one. This is...
THIS IS NOT ANY FINANCIAL ADVICE, just some info. Quite simply this is a short IMO, RSI is at 90! And there is bearish divergence.
All description on the chart. Please, don't forget to like and follow. Thank you.
NVAX shares just broke back above the critical $50 level. Its current pattern is either a constructive pause in a continuing trend, or a failure in the making organized as a violated bearish descending triangle with a bear trigger at $45. The straddle is in play.
Fundamentals : Previous Close- 44.43 Open- 45.55 Bid- 45.00 x 1300 Ask- 45.40 x 1000 Day's Range- 43.60 - 45.76 52 Week Range- 3.54 - 61.50 Volume- 3,231,807 Avg. Volume- 9,264,854 Market Cap- 2.673B Beta (5Y Monthly)- 1.41 PE Ratio (TTM)- N/A EPS (TTM)- -3.83 Earnings Date- May 10, 2020 Forward Dividend & Yield- N/A (N/A) Ex-Dividend Date- N/A 1y...
NOVAVAX close to a breakout point. Risk reward 2:1.